evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

166 questions · 177 findings · 9 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 86 · 48.6%GRADE not reported 8 · 4.5%Very low 44 · 24.9%Low 38 · 21.5%Moderate 1 · 0.6%High 0 · 0%

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide · people at increased risk for developing type 2 diabetes
2 findings from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Surgery vs preoperative pharmacological therapy and surgery

Non‐surgical therapy for recurrent or persistent diseaseRadiation therapy and/or pharmacologic therapy for recurrent or persistent disease · adults with growth‐hormone secreting pituitary adenomas

It is very uncertain whether surgery alone changes non‐surgical therapy for recurrent or persistent diseaseRadiation… compared with preoperative pharmacological therapy and surgery (very low certainty).

1 finding from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + GLP1‐A
2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + DPP4‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).

3 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + thiazolidinedione

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + thiazolidinedione compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + nateglinide
4 findings from 1 review
Show 1 more finding

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + SGLT2‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + SGLT2‐I compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review